The Fc fusion therapeutics market is anticipated to grow at an annualized rate of over 10%, claims Roots Analysis
Since the approval of Enbrel® in 1998 for the treatment of rheumatoid arthritis, Fc fusion therapies have evolved into a prominent class of therapeutics; currently, several therapies are being developed for a variety of disease indications.
For additional details, please visit
https://www.rootsanalysis.com/....reports/fc-fusion-th
Like
Comment
Share
